The Business Research Company
The Business Research Company’s Biopharmaceutical CMO Market Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035
For anyone tracking the life sciences supply chain, the numbers coming out of the contract manufacturing space are hard to ignore. A new report from The Business Research Company reveals that the biopharmaceutical contract manufacturing organization (CMO) sector is on track to nearly double in value over the next five years, driven by an unrelenting rise in chronic disease and the push for faster, more flexible drug production.
Also worth a look: Biopharma logistics outsourcing market to hit $221 billion by 2030 as cold chain demand surges and Bioreactors market poised for 14.6% CAGR surge as biopharma demand climbs.
The Biopharmaceutical CMO Market has already seen rapid enlargement over recent years. According to the analysis, the market is projected to increase from $28.02 billion in 2025 to $32.03 billion in 2026, representing an impressive compound annual growth rate (CAGR) of 14.3%. This historic growth has been fueled by several factors, including the expanding biologics pipeline, heightened clinical trial activity, greater demand for flexible manufacturing options, an increase in biosimilar approvals, and the availability of specialized expertise in biomanufacturing.
Download a free sample of the biopharmaceutical cmo market report:
https://thebusinessresearchcompany.com/sample_request?id=52861647&type=smp&name=Biopharmaceutical%20CMO%20Market%20Report%202026&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Nov_PR
Looking further ahead, the market is expected to continue this upward trajectory, reaching $54.54 billion by 2030 with a CAGR of 14.2%. The anticipated surge during the forecast period is driven by escalating investments in next-generation biologics, growing needs for rapid manufacturing scale-up, expansion of personalized therapies, broader adoption of continuous bioprocessing techniques, and a stronger emphasis on risk-sharing manufacturing partnerships. Key trends include more outsourcing of biologics production, increased demand for biosimilar manufacturing services, widespread use of single-use bioprocessing technologies, growth in cell and gene therapy manufacturing, and a focus on comprehensive end-to-end CMO capabilities.
To understand why these CMOs matter, it helps to look at what they actually do. Biopharmaceutical CMOs provide essential manufacturing services ranging from small-scale production for preclinical research to large-scale manufacturing required for clinical trials and commercial distribution. These organizations play a crucial role in reducing overall operational risks and shortening time-to-market for new therapies. By handling complex manufacturing processes, CMOs help biopharmaceutical companies focus on innovation while ensuring efficiency and quality.
View the full biopharmaceutical cmo market report:
https://thebusinessresearchcompany.com/report/biopharmaceutical-CMO-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Nov_PR
What’s behind this growth spurt? The rising prevalence of chronic diseases is a major factor propelling growth in the biopharmaceutical CMO sector. Chronic diseases, which include conditions such as cardiovascular disease, cancer, respiratory illnesses, and diabetes, require long-term management and are increasing worldwide. Biopharmaceutical CMOs contribute to combating these diseases by speeding up drug development, lowering production costs, and maintaining high standards of quality. This enhances the accessibility and affordability of critical medications.
Consider the scale of the problem: In January 2024, the World Health Organization, a Switzerland-based intergovernmental agency, reported that noncommunicable diseases are responsible for 41 million deaths annually, accounting for 74% of all global deaths and the majority of premature mortality. These diseases disproportionately affect low- and middle-income countries, further emphasizing the importance of efficient drug manufacturing solutions provided by CMOs. This growing health burden is a key driver behind the expanding biopharmaceutical CMO market.
Where is all this activity concentrated? In 2025, North America held the largest share of the biopharmaceutical CMO market, reflecting its well-established pharmaceutical infrastructure and high demand for advanced biologics. Meanwhile, the Asia-Pacific region is expected to experience the fastest growth over the forecast period. The market report also covers other critical regions such as Southeast Asia, Western Europe, Eastern Europe, South America, the Middle East, and Africa, providing a comprehensive view of global market dynamics and opportunities.
Our 2026 reports feature deeper market intelligence with market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, and updated graphics and tables.
Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: marketing@tbrc.info
The Business Research Company – www.thebusinessresearchcompany.com
Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company“
Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X
Why it matters: As chronic diseases now account for 74% of all global deaths, the ability to manufacture biologics and advanced therapies quickly and affordably is no longer just an industry concern—it is a public health imperative. The projected doubling of the CMO market signals that drug developers and governments alike are betting on outsourced manufacturing as a critical tool to meet that challenge.
